Vital Sign Abnormalities, Rapid Response, and Adverse Outcomes in Hospitalized Patients

2012 ◽  
Vol 27 (6) ◽  
pp. 480-486 ◽  
Author(s):  
Kate Fagan ◽  
Allison Sabel ◽  
Philip S. Mehler ◽  
Thomas D. MacKenzie
2018 ◽  
Vol 46 (12) ◽  
pp. 1953-1960 ◽  
Author(s):  
Shannon M. Fernando ◽  
Peter M. Reardon ◽  
Daniel I. McIsaac ◽  
Debra Eagles ◽  
Kyle Murphy ◽  
...  

CHEST Journal ◽  
2018 ◽  
Vol 154 (2) ◽  
pp. 309-316 ◽  
Author(s):  
Shannon M. Fernando ◽  
Peter M. Reardon ◽  
Bram Rochwerg ◽  
Nathan I. Shapiro ◽  
Donald M. Yealy ◽  
...  

2020 ◽  
Vol 36 (3) ◽  
pp. 102-109
Author(s):  
Tahnia Alauddin ◽  
Sarah E. Petite

Background: Contraindications and precautions to metformin have limited inpatient use, and limited evidence exists evaluating metformin in hospitalized patients. Objective: This study aimed to determine the safety and efficacy of inpatient metformin use. Methods: This study was an observational, retrospective, cohort study at an academic medical center between June 1, 2016, and May 31, 2018. Hospitalized adults with type 2 diabetes mellitus receiving at least 1 metformin dose were included. The primary endpoint was to identify hospitalized patients using metformin with at least 1 contraindication or precautionary warning against use. Secondary endpoints included assessing metformin efficacy with glycemic control, characterizing adverse outcomes of inpatient metformin, and comparing the efficacy of metformin-containing regimens. Results: Two hundred patients were included. There were 126 incidences of potentially unsafe use identified in 111 patients (55.5%). The most common reasons were age ≥65 years (47%), heart failure diagnosis (7.5%), and metformin within 48 hours of contrast (6%). Metformin was contraindicated in 2 patients (1%) with an estimated glomerular filtration rate ≤30 mL/min/1.73 m2. The overall median daily blood glucose was 146 mg/dL (interquartile range [IQR] = 122-181). Patients were divided into 3 groups: metformin monotherapy, metformin plus oral antihyperglycemic therapy, and metformin plus insulin. The median daily blood glucoses were 129 mg/dL (IQR = 110-152), 154 mg/dL (IQR = 133-178), and 174 mg/dL (IQR = 142-203; P < .001), respectively. Two patients (1%) developed acute kidney injury, and no patients developed lactic acidosis. Conclusions: Metformin was associated with goal glycemic levels in hospitalized patients with no adverse outcomes. These results suggest the potential for metformin use in hospitalized, non–critically ill patients.


2003 ◽  
Vol 15 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Alessandra Marengoni ◽  
Stefania Cossi ◽  
Monica De Martinis ◽  
Maria K. Ghisla ◽  
Paolo A. Calabrese ◽  
...  

2017 ◽  
Vol 32 (12) ◽  
pp. 752-763 ◽  
Author(s):  
Stephanie M. Ozalas ◽  
Victoria Huang ◽  
Luigi Brunetti ◽  
Timothy Reilly

Sign in / Sign up

Export Citation Format

Share Document